Many of the themes of this blog lately have been centered around the new strategic partnerships Pharma companies have been developing in order to make the industry a more collaborative, streamlined industry where they can learn from on another. Recently, Johnson & Johnson, Eli Lilly, Merck announced a collaboration to create a global database of all clinical trials. The goal is to streamline the process and bring drugs to market faster. Over 100,000 clinical trial investigators have agreed to begin putting clinical trial information into a global database as well as Good Clinical Practice training records and clinical trial infrastructure detail. According to Reuters, Andreas Koester, head of clinical trial innovation/external alliances at J&J's Janssen unit, commented on the new initiative "The feedback we have gotten so far is ... they can't wait to get rid of the administrative burden and red tape."
This coming April at Partnerships in Clinical Trials, Andreas Koester will participate in the Executive Leadership Boardroom, an idea exchange forum with the brightest minds in the industry aimed to propel drug development practices. Sign up to receive updates on the Boardroom and the rest of the 2013 Agenda as details become available.
As we see more and more strategic partnerships between Pharma companies, what impact do you think this will have on the industry as a whole now that companies are working together to bring better drugs to market faster?
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to email@example.com.